Biogen Inc. (NASDAQ:BIIB) Logo

Sabby Management Llc increased its stake in Ophthotech Corp (OPHT) by 23.57% based on its latest 2018Q3 regulatory filing with the SEC. Sabby Management Llc bought 308,742 shares as the company’s stock declined 32.97% with the market. The hedge fund held 1.62 million shares of the major pharmaceuticals company at the end of 2018Q3, valued at $3.82M, up from 1.31 million at the end of the previous reported quarter. Sabby Management Llc who had been investing in Ophthotech Corp for a number of months, seems to be bullish on the $57.36 million market cap company. The stock decreased 0.71% or $0.01 during the last trading session, reaching $1.39. About 95,988 shares traded. Ophthotech Corporation (NASDAQ:OPHT) has declined 46.42% since January 13, 2018 and is downtrending. It has underperformed by 46.42% the S&P500. Some Historical OPHT News: 09/05/2018 – Ophthotech 1Q Loss $13.1M; 09/05/2018 – OPHTHOTECH 1Q COLLABORATION REV $0; 09/05/2018 – Ophthotech 1Q Loss/Shr 36c; 09/05/2018 – OPHTHOTECH 1Q LOSS/SHR 36C, EST. LOSS/SHR 40C (2 EST.); 01/05/2018 – Ophthotech Initial Top-line Data for Study Expected by the End of 2018; 19/04/2018 DJ Ophthotech Corp, Inst Holders, 1Q 2018 (OPHT); 01/05/2018 – Ophthotech Completes Patient Recruitment in the Phase 2a Clinical Trial of Zimura(R) in Combination With Anti-VEGF Therapy in Wet Age-Related Macular Degeneration; 10/05/2018 – Municipal Employees Retire Sys Of Michigan Buys Into Ophthotech

Montecito Bank & Trust decreased its stake in Biogen Inc (BIIB) by 51.05% based on its latest 2018Q3 regulatory filing with the SEC. Montecito Bank & Trust sold 896 shares as the company’s stock declined 6.12% with the market. The institutional investor held 859 shares of the biological products (no diagnostic substances) company at the end of 2018Q3, valued at $303,000, down from 1,755 at the end of the previous reported quarter. Montecito Bank & Trust who had been investing in Biogen Inc for a number of months, seems to be less bullish one the $67.14 billion market cap company. The stock increased 0.61% or $2.02 during the last trading session, reaching $333.21. About 1.32M shares traded. Biogen Inc. (NASDAQ:BIIB) has declined 0.04% since January 13, 2018 and is downtrending. It has underperformed by 0.04% the S&P500. Some Historical BIIB News: 23/04/2018 – BIOGEN: NEW SPINRAZA DATA UNVEILED AT AAN ANNUAL MEETING SHOW; 20/04/2018 – Biogen, Ionis Expect to Close Deal in 2Q; 24/04/2018 – BIOGEN INC – QTRLY SPINRAZA REVENUE OF $364 MLN VS $47 MLN REPORTED LAST YEAR; 29/05/2018 – Biogen at Bernstein Strategic Decisions CEO Conference Tomorrow; 12/03/2018 – BIOGEN DEAL INCL UP TO $515M ADDED MILESTONE PAYMENTS; 27/03/2018 – ICCR: Shareholders Will Vote on Resolutions at AbbVie, Amgen, Biogen, Bristol-Myers Squibb and Eli Lilly; 05/04/2018 – $ABBV $BIIB Settlement on Humira #Biosimilar in Europe -; 04/05/2018 – Ionis Pharmaceuticals Expects Over $2B of Cash Upon Closing of Biogen Collaboration; 24/04/2018 – Biogen Idec 1Q EPS $5.54; 24/04/2018 – BIOGEN INC – QTRLY SHR $5.54

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on January, 29 before the open. They expect $6.72 earnings per share, up 27.76% or $1.46 from last year’s $5.26 per share. BIIB’s profit will be $1.35 billion for 12.40 P/E if the $6.72 EPS becomes a reality. After $7.40 actual earnings per share reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -9.19% negative EPS growth.

Since September 26, 2018, it had 0 insider buys, and 1 sale for $350,000 activity.

Montecito Bank & Trust, which manages about $335.10M US Long portfolio, upped its stake in Ishares Russell 1000 Value Etf (IWD) by 36,137 shares to 142,895 shares, valued at $18.09M in 2018Q3, according to the filing. It also increased its holding in Cisco Systems Inc (NASDAQ:CSCO) by 9,457 shares in the quarter, for a total of 44,155 shares, and has risen its stake in Wisdomtree Emerging Markets (DEM).

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Seekingalpha.com which released: “EMA grants Prime status for Roche’s risdiplam for SMA – Seeking Alpha” on December 17, 2018, also Nasdaq.com with their article: “Surprising Analyst 12-Month Target For QUS – Nasdaq” published on December 18, 2018, Seekingalpha.com published: “Quebec to cover Biogen’s SMA med Spinraza – Seeking Alpha” on December 20, 2018. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Seekingalpha.com and their article: “Biogen down 5%, sell-siders soften outlook – Seeking Alpha” published on December 18, 2018 as well as Nasdaq.com‘s news article titled: “Noteworthy Tuesday Option Activity: BA, BIIB, BHF – Nasdaq” with publication date: December 18, 2018.

Investors sentiment decreased to 1.01 in 2018 Q3. Its down 0.01, from 1.02 in 2018Q2. It fall, as 45 investors sold BIIB shares while 334 reduced holdings. 138 funds opened positions while 243 raised stakes. 167.21 million shares or 1.69% less from 170.10 million shares in 2018Q2 were reported. Ims Capital Management reported 108 shares. Architects has invested 0.01% in Biogen Inc. (NASDAQ:BIIB). New Vernon Capital Hldgs Ii Ltd Liability reported 0.21% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Fdx Inc holds 0.09% or 6,853 shares. Nuveen Asset Limited Co, a Illinois-based fund reported 75,050 shares. Burney holds 0.83% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 39,508 shares. Massachusetts-based Nichols & Pratt Advisers Limited Liability Partnership Ma has invested 0.02% in Biogen Inc. (NASDAQ:BIIB). Glenview Bancorporation Tru Dept invested in 723 shares. 25,510 are held by Bedell Frazier Investment Counseling Ltd Liability Co. Raymond James Associate has 0.23% invested in Biogen Inc. (NASDAQ:BIIB). Williams Jones Assocs Ltd invested in 1,316 shares or 0.01% of the stock. Triangle Wealth has invested 1.25% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Bsw Wealth Ptnrs reported 1,025 shares. The New York-based Jefferies Gp Ltd Liability Co has invested 0.05% in Biogen Inc. (NASDAQ:BIIB). Caxton Assoc Limited Partnership owns 5,867 shares.

Among 35 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 27 have Buy rating, 0 Sell and 8 Hold. Therefore 77% are positive. Biogen Idec Inc. had 147 analyst reports since July 23, 2015 according to SRatingsIntel. BMO Capital Markets maintained the shares of BIIB in report on Friday, March 2 with “Buy” rating. The rating was maintained by BMO Capital Markets with “Market Perform” on Wednesday, July 26. Morgan Stanley maintained the shares of BIIB in report on Wednesday, June 14 with “Hold” rating. Credit Suisse initiated the shares of BIIB in report on Wednesday, January 20 with “Neutral” rating. The firm has “Hold” rating by Credit Suisse given on Thursday, January 25. As per Friday, December 4, the company rating was maintained by Wells Fargo. The stock has “Hold” rating by Cantor Fitzgerald on Tuesday, October 24. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Overweight” rating by Morgan Stanley on Wednesday, July 25. The stock has “Outperform” rating by Bernstein on Wednesday, June 29. The firm earned “Hold” rating on Friday, December 9 by Stifel Nicolaus.

Investors sentiment decreased to 0.79 in 2018 Q3. Its down 0.38, from 1.17 in 2018Q2. It fall, as 9 investors sold OPHT shares while 19 reduced holdings. 10 funds opened positions while 12 raised stakes. 15.12 million shares or 12.14% less from 17.21 million shares in 2018Q2 were reported. Connor Clark And Lunn Limited has 0.01% invested in Ophthotech Corporation (NASDAQ:OPHT). Federated Invsts Inc Pa stated it has 0% in Ophthotech Corporation (NASDAQ:OPHT). Northern Trust Corporation has 74,435 shares for 0% of their portfolio. Boothbay Fund Mgmt Limited Liability Com reported 42,208 shares. Susquehanna Gru Llp holds 0% or 41,501 shares in its portfolio. Dimensional Fund Advsrs Lp has invested 0% in Ophthotech Corporation (NASDAQ:OPHT). Massachusetts-based Bogle Invest Lp De has invested 0.01% in Ophthotech Corporation (NASDAQ:OPHT). Endurance Wealth Mgmt holds 0% or 1,500 shares. Renaissance Technologies Limited Com holds 0% of its portfolio in Ophthotech Corporation (NASDAQ:OPHT) for 683,400 shares. Creative Planning accumulated 0% or 54,275 shares. Goldman Sachs Grp Inc holds 0% or 39,608 shares. State Street reported 41,652 shares or 0% of all its holdings. Moreover, Bridgeway Capital Mngmt Inc has 0% invested in Ophthotech Corporation (NASDAQ:OPHT) for 217,400 shares. Geode Capital Mngmt Limited Com has 173,774 shares. Sabby Mngmt Ltd owns 1.62 million shares.

Sabby Management Llc, which manages about $835.79 million and $781.50M US Long portfolio, decreased its stake in Dbv Technologies Sa (Call) by 161 shares to 116 shares, valued at $261,000 in 2018Q3, according to the filing. It also reduced its holding in Amarin Corporation Plc (Call) by 873 shares in the quarter, leaving it with 9,834 shares, and cut its stake in Zosano Pharma Corp.

More notable recent Ophthotech Corporation (NASDAQ:OPHT) news were published by: Seekingalpha.com which released: “Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19 – Seeking Alpha” on January 07, 2019, also Seekingalpha.com with their article: “Ophthotech Corp (OPHT) CEO Glenn Sblendorio on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” published on August 01, 2018, Benzinga.com published: “Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut – Benzinga” on December 07, 2018. More interesting news about Ophthotech Corporation (NASDAQ:OPHT) were released by: Businesswire.com and their article: “Ophthotech Corporation to Report Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 1, 2018 – Business Wire” published on July 25, 2018 as well as Seekingalpha.com‘s news article titled: “Buy Ophthotech, Get Cash And Zimura For Free – Seeking Alpha” with publication date: March 23, 2017.

Among 13 analysts covering Ophthotech Corporation (NASDAQ:OPHT), 2 have Buy rating, 2 Sell and 9 Hold. Therefore 15% are positive. Ophthotech Corporation had 29 analyst reports since August 4, 2015 according to SRatingsIntel. On Friday, October 27 the stock rating was maintained by Stifel Nicolaus with “Hold”. The stock has “Buy” rating by Chardan Capital Markets on Tuesday, August 4. The rating was maintained by Chardan Capital Markets on Wednesday, July 26 with “Hold”. The stock of Ophthotech Corporation (NASDAQ:OPHT) earned “Outperform” rating by Oppenheimer on Friday, August 14. As per Thursday, August 4, the company rating was maintained by Citigroup. J.P. Morgan downgraded the stock to “Sell” rating in Monday, March 19 report. Barclays Capital downgraded Ophthotech Corporation (NASDAQ:OPHT) on Monday, December 12 to “Equal-Weight” rating. The company was downgraded on Monday, December 12 by Cowen & Co. The firm earned “Overweight” rating on Thursday, June 2 by JP Morgan. On Tuesday, December 13 the stock rating was upgraded by Goldman Sachs to “Neutral”.

Since January 2, 2019, it had 0 buys, and 4 sales for $10,340 activity. Westby Keith sold $389 worth of stock or 299 shares.

Ophthotech Corporation (NASDAQ:OPHT) Institutional Positions Chart




Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *